This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Use of rotigotine
PDMED_ROTIGOTINE
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
395 |
4. Check minimum number of events
Min. number of events
3
|
395 |
5. Include endpointsNone |
395 |
6. Filter based on genotype QC (FinnGen only) |
384 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF2
Use of rotigotine
based on the number of shared cases.
Similar with more cases:
Similar with less cases:
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 384 | 218 | 166 |
| Unadjusted period prevalence (%) | 0.08 | 0.08 | 0.08 |
| Median age at first event (years) | 64.50 | 64.02 | 65.12 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 395
- Matched controls
- 3950
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
N04BD02
ATC
rasagiline; oral
325.2
307.7
188
11
N04BD01
ATC
selegiline; oral
260.8
307.7
230
21
N04BA02
ATC
levodopa and decarboxylase inhibitor; oral
295.9
307.7
324
60
G20
ICD-10 Finland
Parkinson disease
287.8
307.7
308
48
N04BC05
ATC
pramipexole; oral
49.7
307.7
277
178
N04BA03
ATC
levodopa, decarboxylase inhibitor and COMT inhibitor; oral
357.7
307.7
206
12
N87
ICPC
Parkinsonism
145.4
307.7
168
20
N04BC04
ATC
ropinirole; oral
384.1
307.7
213
12
110
Kela drug reimbursment
Parkinson's disease and comparable movement disrorders
304.9
307.7
309
46
N04BC09
ATC
rotigotine; transdermal
+∞
307.7
395
*
193
Kela drug reimbursment
Rasagiline
281.9
161.4
155
9
N03AE01
ATC
clonazepam; systemic
14.9
116.3
119
111
N04BB01
ATC
amantadine; oral
43.1
101.4
62
17
G25.9
ICD-10 Finland
Extrapyramidal and movement disorder, unspecified
38.9
76.7
48
14
G25.8
ICD-10 Finland
Other specified extrapyramidal and movement disorders
14.2
66.8
65
54
N06DA03
ATC
rivastigmine; oral, transdermal
10.6
63.0
76
87
R25.1
ICD-10 Finland
Tremor, unspecified
14.0
62.3
61
51
N05AH04
ATC
quetiapine; oral
5.6
57.4
148
380
AAG20
NOMESCO Finland
Stereotactic intracranial implantation of electrodes
102.8
56.7
61
7
N04AA02
ATC
biperiden; systemic
18.3
56.5
47
29
N04BX02
ATC
entacapone; oral
212.3
54.5
55
*
F02.39*G20
ICD-10 Finland
Dementia in Parkinson's disease without information on additional symptoms
85.0
47.3
52
7
XA800
NOMESCO Finland
Neuropsychological investigation
9.8
44.6
55
64
G04BD12
ATC
mirabegron; oral
4.6
39.3
118
333
AA1AD
NOMESCO Finland
CT of head and brain
3.9
39.1
190
758
AEA50
NOMESCO Finland
Adjustment of implanted neurostimulator
80.0
38.8
43
6
N04BX04
ATC
opicapone; oral
415.6
38.7
38
*
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
10.4
36.9
43
46
N03AX12
ATC
[U] gabapentin; oral
4.0
35.5
138
467
SPAT1229
SPAT
Assessment of need for aid
5.2
33.3
78
178
L28
ICPC
Limited function/disability (L)
3.8
32.2
132
460
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
5.6
32.0
68
142
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
4.0
30.9
111
352
R4130
NOMESCO Finland
Speech therapy
9.8
29.9
36
40
N06AX11
ATC
mirtazapine; oral
3.2
29.2
200
949
A28
ICPC
Limited function/disability NOS
3.7
28.8
120
419
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
4.5
28.0
80
213
SPAT1231
SPAT
Assessment of adjustments needed in living environment
10.1
26.5
31
33
AEA00
NOMESCO Finland
Replacement of impulse generator of stimulation device in the nervous system
32.6
25.4
33
11
SPAT1215
SPAT
Assessment of need for medical rehabilitation
6.7
25.1
42
69
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
4.7
23.6
60
145
C07AA05
ATC
propranolol; systemic
3.1
22.6
125
511
N19
ICPC
Speech disorder
24.8
21.6
30
13
K59.09
ICD-10 Finland
Constipation, unspecified
4.4
21.4
60
156
R53
ICD-10 Finland
Malaise and fatigue
2.9
21.1
142
644
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
3.1
21.0
108
422
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.1
20.9
112
448
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.7
20.6
172
870
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
4.0
20.6
64
180
R1250
NOMESCO Finland
Evaluation of functional capability
7.5
20.2
30
43
ZXM20
NOMESCO Finland
Intraoperative use of computerised tomography
19.0
19.9
30
17
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
4.2
19.6
57
152
N03AX16
ATC
[U] pregabalin
2.8
19.3
141
663
SPAT1217
SPAT
Assessment of need for services (elderly/care support)
4.0
19.0
59
165
I95.1
ICD-10 Finland
Orthostatic hypotension
5.5
16.6
33
64
SPAT1216
SPAT
Assessment of functional ability
2.8
16.4
99
417
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.9
16.3
95
393
N06AX21
ATC
duloxetine; oral
3.2
15.5
71
256
ZXM10
NOMESCO Finland
Intraoperative use of conventional X-ray imaging
3.7
15.4
52
154
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
4.0
14.7
45
124
N06AX16
ATC
venlafaxine; oral
2.9
14.7
81
324
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
2.3
14.3
159
888
R47.1
ICD-10 Finland
Dysarthria and anarthria
15.2
14.2
23
16
M03BX01
ATC
baclofen; systemic
6.8
13.8
22
34
SPAT1224
SPAT
Implementation of speech therapy rehabilitation plan
12.7
13.8
24
20
N28
ICPC
Limited function/disability (N)
11.5
13.7
25
23
N05BA04
ATC
oxazepam; oral
2.4
13.7
133
698
Q79.6
ICD-10 Finland
Ehlers-Danlos syndrome
+∞
13.6
13
*
N04BC07
ATC
apomorphine; parenteral
+∞
13.6
13
*
A06AD11
ATC
lactulose; oral
2.8
13.6
82
343
K59.00
ICD-10 Finland
Constipation caused by slow bowel passage (SCT)
5.9
13.5
25
45
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
4.6
13.1
32
74
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
3.2
13.0
55
188
R13
ICD-10 Finland
Dysphagia
3.3
12.8
51
168
H02AA02
ATC
fludrocortisone; oral
16.1
12.7
20
13
U04
ICPC
Incontinence urine
3.7
12.7
42
122
YX8AD
NOMESCO Finland
Stereotactic CT examination for dose design of radiotherapy
72.2
12.7
14
*
SPAT1226
SPAT
Implementation of occupational therapy rehabilitation plan
5.9
12.6
23
41
R5110, ,
SPAT
3.6
12.4
43
129
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.6
12.4
83
365
SPAT1234
SPAT
Support of social functional capacity
4.1
12.4
35
91
Z2445
NOMESCO Finland
Psychologist
4.8
12.1
28
62
A04
ICPC
Weakness/tiredness general
2.6
12.0
77
331
G93.3
ICD-10 Finland
Postviral fatigue syndrome
36.2
11.3
14
*
N02AA05
ATC
oxycodone; systemic
2.3
11.3
100
499
R35
ICD-10 Finland
Polyuria
3.2
11.2
46
154
N29
ICPC
Neurological sympt/complt other
9.3
10.9
22
25
R1260
NOMESCO Finland
Evaluation of communicative skills
5.8
10.8
20
36
N04BC06
ATC
cabergoline; oral
28.9
10.8
14
5
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
3.7
10.6
35
102
N30.0
ICD-10 Finland
Acute cystitis
2.5
10.6
77
351
F02.39
ICD-10 Finland
Dementia in Parkinson's disease without information on additional symptoms
+∞
10.5
10
*
AA5EN
NOMESCO Finland
Brain reseptor or transprot protein distribution isotope imaging
33.5
10.4
13
*
S01.0
ICD-10 Finland
Open wound of scalp
3.0
10.2
47
169
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.4
10.0
81
386
SPAT1137
SPAT
Taking care of patient’s/customer’s hygiene
3.3
10.0
40
132
WX402
NOMESCO Finland
General anaesthesia
2.2
9.8
99
518
N02BE01
ATC
paracetamol; systemic, rectal
3.6
9.7
370
3184
L03
ICPC
Low back symptom/complaint
2.1
9.5
126
733
R60.0
ICD-10 Finland
Localized oedema
2.5
9.4
68
308
N06AB10
ATC
escitalopram; oral
2.2
9.3
89
455
N39.4
ICD-10 Finland
Other specified urinary incontinence
2.7
9.2
55
227
M01AH05
ATC
etoricoxib; oral
2.0
9.2
262
1971
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
1.9
9.2
193
1312
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
3.8
9.2
28
77
M54.5
ICD-10 Finland
Low back pain
2.0
9.2
157
997
UDQ42
NOMESCO Finland
Endoscopic assessment of swallowing function
37.6
9.1
11
*
M48.0
ICD-10 Finland
Spinal stenosis
2.4
9.1
73
347
M79.6
ICD-10 Finland
Pain in limb
1.9
9.0
185
1246
XXA00
NOMESCO Finland
Clinical examination requiring general anaesthesia
24.7
9.0
12
5
G21.9
ICD-10 Finland
Secondary parkinsonism, unspecified
24.7
9.0
12
5
D21
ICPC
Swallowing problem
8.3
9.0
19
24
JDB10
NOMESCO Finland
Percutaneous gastrostomy
12.9
8.9
15
12
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
3.8
8.9
27
74
J01EA01
ATC
trimethoprim; systemic
2.0
8.9
120
700
N04
ICPC
Restless legs
28.2
8.5
11
*
N02BF01
ATC
gabapentin; oral
2.8
8.5
46
180
TJD10
NOMESCO Finland
Insertion of other tube into stomach or duodenum
91.9
8.4
9
*
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
2.5
8.4
56
244
AAW01
NOMESCO Finland
Implantation of intracranial stimulation device
+∞
8.4
8
*
WX725
NOMESCO Finland
Noninvasive ventilation
3.3
8.3
32
103
Z01.8
ICD-10 Finland
Other specified special examinations
2.0
8.3
108
620
L17
ICPC
Foot/toe symptom/complaint
1.9
8.3
133
821
C03CA01
ATC
furosemide; systemic
1.9
8.2
137
855
R26.8
ICD-10 Finland
Other and unspecified abnormalities of gait and mobility
4.9
8.2
18
38
NA7EA
NOMESCO Finland
Scoliosis X-ray examination
9.2
8.1
16
18
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.4
8.1
60
274
SPAT1301
SPAT
No procedures
1.9
8.1
141
893
WX002
NOMESCO Finland
Sedation and analgesia
2.1
8.1
97
540
SPAT1254
SPAT
Administration of medicine
2.3
7.9
68
331
ZXE13
NOMESCO Finland
Procedure duration 90 to 119 minutes
4.2
7.9
21
52
SPAT1295
SPAT
Other function in accordance with physical therapy nomenclature
3.2
7.8
31
102
XF606
NOMESCO Finland
Ortostatic test
15.4
7.8
12
8
UKC02
NOMESCO Finland
Cystoscopy
2.2
7.8
77
398
N02BF02
ATC
pregabalin; oral
3.0
7.7
34
119
SPAT1262
SPAT
Handing over of treatment supplies
2.1
7.6
85
459
J69.0
ICD-10 Finland
Pneumonitis due to food and vomit
7.4
7.6
17
24
G23.9
ICD-10 Finland
Degenerative disease of basal ganglia, unspecified
81.6
7.4
8
*
TAW99
NOMESCO Finland
Other minor neurosurgical procedure
13.7
7.4
12
9
M35.7
ICD-10 Finland
Hypermobility syndrome
13.7
7.4
12
9
XKD00
NOMESCO Finland
Uroflowmetry
2.1
7.3
73
378
L86
ICPC
Back syndrome with radiating pain
2.9
7.2
35
129
M47.9
ICD-10 Finland
Spondylosis, unspecified
4.2
7.2
19
47
K04.08
ICD-10 Finland
Other specified pulpit
3.0
7.1
32
113
S72.0
ICD-10 Finland
Fracture of neck of femur
3.6
7.1
23
66
SPAT1156
SPAT
Guidance concerning treatment of rash and skin
2.2
7.1
67
339
M54.4
ICD-10 Finland
Lumbago with sciatica
2.1
7.0
79
427
A02BC03
ATC
lansoprazole; oral
1.8
7.0
133
858
Z04.9
ICD-10 Finland
Examination and observation for unspecified reason
3.5
6.9
24
72
AA1BD
NOMESCO Finland
Extensive CT of head and brain
4.2
6.9
18
44
TPH04
NOMESCO Finland
Cathetrisation of vein
1.9
6.8
96
563
OAB73, ,
SPAT
40.8
6.8
8
*
N02AX02
ATC
tramadol; systemic, rectal
1.7
6.6
186
1340
N06CA01
ATC
amitriptyline and psycholeptics; systemic
2.3
6.5
51
238
ZY010
NOMESCO Finland
Hospital outpatient
3.3
6.5
24
75
Z50.1
ICD-10 Finland
Other physical therapy
2.8
6.5
33
125
WX704
NOMESCO Finland
Intubation
2.6
6.5
37
149
X59
ICD-10 Finland
Exposure to unspecified factor
2.0
6.5
81
455
G31.8
ICD-10 Finland
Other specified degenerative diseases of nervous system
18.4
6.3
9
5
WX110
NOMESCO Finland
Infiltration anesthesia
1.8
6.2
274
2219
H02.3
ICD-10 Finland
Blepharochalasis
2.6
6.2
37
153
307
Kela drug reimbursment
Tacrine, donepezil, rivastigmine, galantamine and other major and expensive drugs used to treat Alzheimer's disease
3.9
6.2
18
48
A02BC05
ATC
esomeprazole; systemic
1.7
6.1
170
1213
SPAT1148
SPAT
Treatment of chronic ulcer or burn
2.1
6.1
66
351
G25.0
ICD-10 Finland
Essential tremor
3.7
6.1
19
53
NA3AD
NOMESCO Finland
Lumbar spine and sacrum CT examination
3.7
6.1
19
53
D12
ICPC
Constipation
3.0
6.0
26
90
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
317
2212
3.19
19.71
6.9
4.5
8988.33
2622.59
e6/l
—
6
41
264
1695
2.68
18.88
6.8
6.5
1.21
1.22
mmol/l
0.87
221
1449
291
1991
2.75
17.77
5.6
4.6
6.32
6.73
mmol/l
4.43
281
1864
247
1566
2.54
17.64
6.7
5.6
1.21
1.22
mmol/l
1.57
229
1421
209
1229
2.49
17.56
3.8
3.1
—
—
—
0
0
186
1041
2.49
17.36
2.6
2.1
223.05
174.02
u/l
0.32
180
970
140
728
2.43
14.89
1.8
1.8
384.42
451.22
pmol/l
2.44
120
589
130
662
2.44
14.41
1.9
1.7
1412.76
1257.45
nmol/l
0.89
97
495
135
711
2.37
13.78
2.8
2.5
5.75
4.77
e6/l
0.49
125
640
174
1028
2.24
13.45
3.8
3.1
23.98
120.29
e6/l
0.89
137
793
241
1623
2.24
13.45
5.5
3.8
0.00
0.00
estimate
0.50
53
337
90
399
2.63
13.27
4.5
7.4
1.48
1.25
mmol/l
0.24
77
325
163
945
2.23
13.13
3.7
3.0
0.26
0.43
e6/l
1.02
130
706
241
1634
2.22
13.07
6.9
5.0
0.00
0.00
estimate
-0.00
54
311
243
1654
2.22
13.04
5.4
3.7
0.00
0.01
estimate
0.50
52
302
241
1643
2.20
12.77
11.5
13.0
1.19
1.25
inr
0.67
69
476
207
1354
2.11
11.92
4.6
2.6
136.43
128.48
ug/l
0.25
184
1235
219
1466
2.11
11.82
5.3
4.6
35.45
35.45
g/l
0.00
203
1367
144
837
2.13
11.15
1.7
1.6
19.32
20.81
nmol/l
0.63
127
700
204
1391
1.96
9.82
2.4
2.0
89.47
95.30
pmol/l
1.24
121
682
190
1265
1.97
9.81
5.7
3.9
—
—
—
0
0
147
900
2.01
9.62
5.7
4.0
0.00
0.01
estimate
0.50
49
309
377
3296
4.16
9.29
22.5
14.6
24.76
23.63
mg/l
0.30
327
2634
324
2635
2.28
9.17
6.9
7.6
77.68
79.27
u/l
0.31
307
2462
219
1553
1.92
9.15
2.7
2.5
—
—
—
0
0
101
549
2.13
9.05
2.3
1.8
—
—
—
0
0
123
720
2.03
9.03
5.9
4.2
1.02
1.02
kg/l
0.45
20
95
79
392
2.27
8.86
2.2
1.7
—
—
—
0
0
50
203
2.68
8.63
1.5
1.3
—
—
—
0
0
78
396
2.21
8.24
2.3
1.8
—
—
—
0
0
98
548
2.05
8.05
2.8
1.8
28.84
29.49
s
0.77
92
527
193
1351
1.84
8.05
4.2
3.8
32.54
56.63
ng/l
0.45
148
993
102
580
2.02
8.00
3.2
2.7
2.55
1.09
e6/l
0.49
58
324
311
2549
2.03
7.72
4.2
3.9
15.08
14.91
pmol/l
0.50
278
2274
127
803
1.86
7.17
2.8
2.1
3.08
3.28
mg/l
0.28
102
687
70
365
2.12
6.86
5.5
3.4
—
—
—
0
0
382
3469
4.07
6.75
26.1
16.9
139.85
139.67
mmol/l
0.80
374
3375
46
205
2.41
6.54
2.3
1.6
—
—
—
0
0
382
3480
3.97
6.48
26.5
17.0
3.95
3.98
mmol/l
1.55
374
3383
84
490
1.91
5.98
4.5
2.2
2.23
2.35
g/l
1.22
75
452
90
544
1.85
5.72
4.4
2.2
13.80
12.85
umol/l
0.52
80
505
162
1160
1.67
5.67
2.8
3.4
2.33
2.36
mmol/l
1.86
147
1021
49
240
2.19
5.60
1.5
1.6
—
—
—
0
0
20
62
3.34
5.52
3.8
2.6
16.35
15.96
%
0.16
11
28
88
538
1.82
5.37
3.5
3.0
2.97
2.40
e6/l
0.18
44
290
296
2497
1.74
5.33
4.3
4.2
12.41
12.36
mm/h
0.02
269
2296
347
3074
2.06
5.33
5.2
4.7
1.92
2.33
mu/l
0.51
319
2781
55
292
2.03
5.10
2.9
3.8
1.22
1.23
mmol/l
1.31
47
252
151
1087
1.63
5.04
3.1
3.1
28.89
31.68
u/l
0.40
141
1030
386
3644
3.60
5.02
31.9
21.6
247.56
246.84
e9/l
0.09
377
3548
386
3645
3.59
5.02
31.9
21.6
4.34
4.47
e12/l
5.28
377
3539
386
3643
3.61
5.02
32.0
21.6
38.84
40.11
%
3.06
343
3391
58
318
1.97
4.92
2.3
1.8
392.04
378.65
nmol/l
0.20
53
296
386
3647
3.56
4.87
32.1
21.7
130.60
135.17
g/l
7.48
380
3587
148
1068
1.62
4.85
2.5
3.0
1122.13
1100.30
ng/l
0.03
123
904
99
647
1.71
4.75
4.5
3.6
74.88
203.48
ng/l
1.60
77
534
181
1377
1.58
4.72
2.6
2.2
75.22
77.83
nmol/l
0.70
163
1210
77
476
1.77
4.48
4.8
2.2
23.80
21.92
%
0.54
62
406
48
261
1.96
4.17
2.1
3.2
144.49
183.31
ng/l
0.43
41
234
146
1089
1.54
3.99
2.3
2.4
56.62
61.74
u/l
0.33
133
1004
224
1832
1.51
3.96
4.5
6.3
10.64
11.27
umol/l
0.72
209
1727
6
6
10.13
3.51
1.0
1.2
—
—
—
0
0
221
1836
1.46
3.40
2.8
2.7
—
—
—
0
0
14
48
2.99
3.33
1.6
1.4
111.93
105.00
u/ml
—
7
10
103
741
1.53
3.23
2.2
1.6
0.92
1.31
mg/l
1.85
89
581
110
803
1.51
3.22
2.6
2.3
—
—
—
0
0
94
664
1.55
3.20
3.0
2.9
2.42
2.46
mmol/l
2.97
83
588
18
74
2.50
3.09
1.6
1.3
3.50
17.79
e6/l
0.79
12
57
9
21
4.36
3.01
1.4
1.7
—
—
—
0
0
50
308
1.71
2.94
5.7
3.2
3.05
2.12
mmol/l
1.24
39
252
65
435
1.59
2.79
6.4
7.4
—
—
—
0
0
37
212
1.82
2.78
1.2
1.4
—
57.70
—
0
18
22
107
2.12
2.62
1.5
1.4
245.47
286.11
ug/g
0.41
14
67
17
75
2.32
2.54
1.1
1.1
—
—
—
0
0
27
145
1.93
2.48
1.7
1.9
1.35
4.11
ug/l
0.70
22
128
14
57
2.51
2.47
1.2
1.2
—
—
—
0
0
49
316
1.63
2.45
3.4
2.4
41.83
32.59
u/l
0.31
42
260
372
3534
1.90
2.39
11.0
10.9
18.87
25.86
u/l
20.04
351
3394
19
92
2.12
2.31
1.7
1.3
32.77
29.98
iu/l
0.13
19
77
11
40
2.80
2.29
1.1
1.1
—
—
—
0
0
7
18
3.94
2.26
2.3
2.2
—
—
—
0
0
8
24
3.38
2.19
1.6
1.9
—
—
—
0
0
18
88
2.10
2.15
1.4
1.9
—
—
—
0
0
7
20
3.54
2.06
1.7
2.0
—
—
—
0
0
222
1945
1.32
2.01
7.1
9.1
4.18
4.10
e9/l
0.18
199
1706
18
91
2.02
1.98
3.2
2.4
26.81
24.74
mmol/l
1.76
18
91
7
21
3.37
1.97
1.7
2.0
—
—
—
0
0
15
71
2.16
1.94
1.3
1.3
—
—
—
0
0
182
1565
1.30
1.83
5.8
5.7
59.70
57.61
%
1.75
170
1466
24
139
1.77
1.80
1.8
1.5
—
—
—
0
0
15
74
2.07
1.77
3.1
2.5
8.73
7.83
kpa
1.52
15
74
307
2849
1.35
1.69
28.0
17.3
14.38
15.11
%
2.04
300
2806
183
1589
1.28
1.67
5.7
6.0
25.41
27.44
%
1.81
170
1487
5
14
3.60
1.62
1.4
3.7
—
—
—
0
0
5
14
3.60
1.62
1.4
3.7
—
—
—
0
0
13
63
2.10
1.61
1.8
1.3
—
—
—
0
0
13
63
2.10
1.61
1.8
1.3
—
—
—
0
0
13
66
2.00
1.45
1.2
1.6
—
—
—
0
0
14
249
0.55
1.43
2.2
1.9
—
—
—
0
0
15
81
1.89
1.42
1.2
1.7
—
—
—
0
0
7
29
2.44
1.40
1.6
2.0
—
—
—
0
0
11
53
2.11
1.39
1.4
1.7
—
—
—
0
0
15
82
1.86
1.37
1.7
1.6
—
—
—
0
0
239
2176
1.25
1.36
3.2
3.1
38.34
52.20
u/l
1.74
215
2010
85
690
1.30
1.28
1.3
1.2
1.55
1.61
u/ml
0.03
20
191
19
115
1.69
1.27
2.3
2.1
200.99
267.43
ug/l
0.35
19
105
18
108
1.70
1.24
2.1
1.6
0.00
0.05
g/l
0.50
18
101
16
93
1.75
1.23
2.2
1.4
—
—
—
0
0
17
101
1.71
1.22
1.3
1.2
—
—
—
0
0
72
577
1.30
1.19
1.4
1.3
32.02
42.47
iu/ml
0.40
22
178
42
310
1.40
1.18
2.6
2.4
6.74
6.06
ug/l
0.12
35
275
17
102
1.70
1.18
1.9
1.7
—
—
—
0
0
17
102
1.70
1.18
2.1
1.6
0.00
0.00
g/l
-0.00
17
96
50
382
1.35
1.15
3.2
2.7
6.52
8.44
umol/l
0.35
45
339
17
103
1.68
1.14
2.1
1.6
0.00
0.00
g/l
-0.00
17
96
8
40
2.02
1.12
1.5
1.9
—
—
—
0
0
13
73
1.81
1.12
2.0
1.5
—
—
—
0
0
16
96
1.69
1.12
1.1
1.2
—
—
—
0
0
16
97
1.68
1.08
1.1
1.2
—
—
—
0
0
5
22
2.29
1.03
1.0
1.0
—
—
—
0
0
12
68
1.79
1.01
2.6
1.2
—
—
—
0
0
7
35
2.02
1.00
1.0
1.1
—
—
—
0
0
0
29
0.00
0.98
0.0
1.5
—
—
—
0
0
10
54
1.87
0.97
1.5
2.7
104.80
105.69
mmol/l
—
10
54
7
37
1.91
0.94
1.1
1.1
—
—
—
0
0
109
944
1.21
0.94
4.5
4.2
22.26
20.88
%
0.43
56
458
105
907
1.21
0.93
2.1
2.6
325.48
8352.36
umol/l
4.42
90
769
6
29
2.08
0.89
1.0
1.2
—
—
—
0
0
329
3160
1.25
0.88
19.7
13.6
83.92
78.50
ml/min/173m2
4.39
290
2614
307
3194
0.83
0.82
3.9
4.2
1.17
1.29
mmol/l
2.76
269
2897
341
3295
1.26
0.81
4.5
4.8
5.91
6.00
mmol/l
0.70
303
2999
98
1118
0.84
0.80
4.0
3.7
18.41
7.54
mg/mmol
0.71
66
679
0
26
0.00
0.78
0.0
1.0
—
—
—
0
0
17
115
1.50
0.78
1.5
1.8
—
216.67
—
0
6
27
201
1.37
0.76
3.4
3.6
3.10
1.67
mmol/l
1.29
22
156
7
39
1.81
0.73
1.1
1.1
—
—
—
0
0
9
56
1.62
0.73
1.0
1.1
—
—
—
0
0
9
56
1.62
0.73
1.2
3.5
54.78
59.25
%
—
9
56
319
3296
0.83
0.71
4.4
4.6
1.47
1.48
mmol/l
0.08
287
3007
5
27
1.86
0.68
1.0
1.2
—
68.00
—
0
5
26
197
1.34
0.68
1.4
1.2
57.05
139.11
iu/ml
—
6
79
5
94
0.53
0.67
1.2
1.3
—
—
—
0
0
7
43
1.64
0.67
1.4
1.2
0.73
0.54
nmol/l
—
7
38
5
28
1.80
0.66
1.0
1.0
—
—
—
0
0
14
95
1.49
0.65
1.4
1.4
—
—
—
0
0
5
30
1.67
0.61
1.0
1.2
—
—
—
0
0
5
30
1.67
0.61
1.0
1.2
—
—
—
0
0
8
52
1.55
0.60
1.6
1.8
—
—
—
0
0
9
60
1.51
0.54
1.4
2.1
—
—
—
0
0
6
38
1.59
0.54
1.8
1.5
—
—
—
0
0
40
472
0.83
0.49
1.5
1.4
—
—
—
0
0
63
554
1.16
0.48
1.4
1.3
1.45
13.75
u/ml
3.40
25
212
324
3318
0.87
0.46
4.4
4.7
4.58
4.65
mmol/l
0.51
291
3049
19
147
1.31
0.46
1.1
1.3
—
—
—
0
0
5
31
1.62
0.43
1.0
1.2
—
—
—
0
0
5
31
1.62
0.43
1.0
1.2
—
—
—
0
0
5
31
1.62
0.43
1.0
1.2
—
—
—
0
0
126
1170
1.11
0.43
4.8
4.8
2.00
2.32
ug/l
0.46
117
1036
8
58
1.39
0.41
1.6
1.7
—
—
—
0
0
0
17
0.00
0.40
0.0
2.6
—
—
—
0
0
0
17
0.00
0.40
0.0
2.6
—
—
—
0
0
8
60
1.34
0.40
1.6
1.7
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
42.83
—
0
18
0
18
0.00
0.40
0.0
1.1
—
116.78
—
0
18
39
450
0.85
0.39
3.7
4.6
35.67
31.82
%
1.06
27
296
11
80
1.39
0.39
1.3
1.2
—
—
—
0
0
5
36
1.39
0.38
2.8
1.6
—
—
—
0
0
5
80
0.62
0.35
1.2
1.4
—
—
—
0
0
32
275
1.18
0.34
3.3
2.6
79.56
62.27
ml/min/173m2
—
9
119
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
14
109
1.29
0.34
7.6
2.2
0.28
0.37
u/ml
—
6
62
6
47
1.28
0.32
1.2
1.5
—
—
—
0
0
11
83
1.33
0.32
1.4
1.9
—
—
—
0
0
14
112
1.26
0.28
2.1
3.3
—
2.37
—
0
14
11
85
1.30
0.28
1.4
1.9
—
—
—
0
0
102
1079
0.93
0.25
3.2
3.1
7.74
7.41
mmol/l
0.33
92
897
9
76
1.19
0.25
1.1
1.3
—
36.42
—
0
8
334
3387
0.91
0.24
4.9
5.3
2.69
2.73
mmol/l
0.34
300
3089
13
158
0.82
0.24
1.1
1.0
—
—
—
0
0
322
3171
1.08
0.22
6.2
6.0
39.57
40.09
mmol/mol
0.51
291
2933
10
79
1.27
0.22
1.2
1.3
—
2.80
—
0
6
0
11
0.00
0.21
0.0
1.2
—
454.33
—
0
6
0
11
0.00
0.21
0.0
1.8
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
9.38
—
0
11
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
2.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
2.9
—
—
—
0
0
0
13
0.00
0.21
0.0
2.9
—
—
—
0
0
0
13
0.00
0.21
0.0
2.9
—
—
—
0
0
6
48
1.25
0.20
1.8
1.3
—
—
—
0
0
0
14
0.00
0.20
0.0
1.3
—
—
—
0
0
8
71
1.13
0.16
1.6
1.7
—
—
—
0
0
15
130
1.16
0.16
1.7
1.9
—
—
—
0
0
12
102
1.18
0.15
1.2
1.3
—
21.40
—
0
7
65
682
0.94
0.13
3.4
2.9
0.67
0.74
ug/l
0.48
45
460
13
113
1.16
0.13
1.3
1.9
—
—
—
0
0
48
454
1.07
0.12
1.4
1.4
—
—
—
0
0
14
124
1.13
0.11
1.6
1.7
—
—
—
0
0
10
114
0.87
0.09
1.5
1.2
1.23
1.20
g/l
—
10
109
11
123
0.89
0.08
1.5
3.1
—
—
—
0
0
6
74
0.81
0.07
1.3
1.1
—
10.78
—
0
10
93
952
0.97
0.07
1.7
1.7
1.36
1.36
mmol/l
0.00
77
791
20
188
1.07
0.05
1.6
1.9
—
—
—
0
0
10
90
1.11
0.05
1.1
1.4
—
—
—
0
0
10
108
0.92
0.03
1.4
1.2
0.25
0.24
g/l
—
10
103
39
389
1.00
0.00
2.8
4.1
2.29
41.51
ug/l
1.19
30
328
10
97
1.03
0.00
1.2
1.3
—
7.35
—
0
20
10
97
1.03
0.00
1.0
1.3
—
—
—
0
0
10
96
1.04
0.00
1.2
1.3
—
2.67
—
0
16
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
2.5
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
17
170
1.00
-0.00
1.5
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
77.50
—
0
6
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
52
0.96
-0.00
3.6
3.1
—
725.29
—
0
7
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
14.66
—
0
5
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
5
53
0.94
-0.00
1.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: PDMED_ROTIGOTINE – Use of rotigotine
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).